Rebecca Mercieca‐Bebber

The University of Sydney — Australia

Economics, Econometrics and Finance · Social Sciences

31h-index3.9kcitations97works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(29), Cancer survivorship and care(22), Palliative Care and End-of-Life Issues(15), Meta-analysis and systematic reviews(12), Gastric Cancer Management and Outcomes(11)

Publications94 total

RoLaCaRT-1: pilot randomised phase II study of robotic vs laparoscopic hemicolectomy for right colon cancer
Surgical Endoscopy·2025Open Access
United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument
The European Journal of Health Economics·2025· 1 citedOpen Access
Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials
Gastric Cancer·2025Open Access
1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
Annals of Oncology·2025
1089P Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer
Annals of Oncology·2025
Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial.
Journal of Clinical Oncology·2025· 2 cited
Survivorship care plan utilization in Australia and New Zealand: survivors’, parents’ and healthcare providers’ perspectives
Supportive Care in Cancer·2025Open Access
Strategies to promote the completion of patient-reported outcome measures by culturally and linguistically diverse and Indigenous Peoples in clinical care settings: A systematic review
Quality of Life Research·2025· 2 citedOpen Access
Development and validation of a prognostic model for advanced gastric and oesophageal carcinoma (AGOC) using individual patient data from two clinical trials.
Journal of Clinical Oncology·2025
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Clinical Colorectal Cancer·2024
Strategies to promote the completion of patient-reported outcome measures by culturally and linguistically diverse and Indigenous Peoples in clinical care settings: a systematic review.
2024Open Access
Acceptability and timing considerations when administering patient-reported outcome measures (PROMs) among people with chronic health conditions who are culturally and linguistically diverse (CALD): a qualitative study protocol
BMJ Open·2024· 2 citedOpen Access
Comparable Real-World Patient-Reported Outcomes Data Across Health Conditions, Settings, and Countries: The PROMIS International Collaboration
NEJM Catalyst·2024· 18 cited
Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials
Current Medical Research and Opinion·2024· 1 cited
Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms
Quality of Life Research·2024· 4 citedOpen Access
AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).
Journal of Clinical Oncology·2024
Recommendations to address respondent burden associated with patient-reported outcome assessment
Nature Medicine·2024· 86 citedOpen Access
A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion
BJUI Compass·2024· 2 citedOpen Access
Agitg Monarcc: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients with Ras and Braf Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (Agitg)
SSRN Electronic Journal·2024Open Access
United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
PharmacoEconomics - Open·2023· 10 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Madeleine King(37), Melanie Calvert(20), Michael Brundage(12), Derek Kyte(11), Daniel Costa(10), Claudia Rutherford(10), Martin R. Stockler(9), Richard Norman(9), Galina Velikova(8), David Cella(8), Rosalie Viney(7), A. Simon Pickard(7), Fabio Efficace(7), Dennis A. Revicki(6), Heather Draper(6), Michael Friedländer(6), Olalekan Lee Aiyegbusi(6), Julia Brown(5), Michael Palmer(5), Margaret-Ann Tait(5)